Amarin Corp Plc (AMRN)

[sts66]

Yeah, guess I agree that V at least stopped calcified plaque progression - but if you look at Table 2 (sorry for formatting) my lack of stats knowledge shows up - I see baseline and followup unadjusted number are 3.6 for both, which I inferred meant "does nothing", or "doesn't reduce" - the SD adjustment is where I lose track of how 3.6/3.6 can lead to -1%, and I ignored the growth in the placebo group of +15%. Adjusted p was 0.053 too, technically non-stat sig - and it's adjusted for what, the SD?


Table 2 Plaque changes by treatment group Treatment group
Baseline Follow-up Difference GLM modelling
Plaque type Mean (SD)
a
Mean (SD)
a
Mean (SD)
a
Unadj. P Adj. P %chg
Calci?cation IPE 3.6 (2.0) 3.6 (1.9) 0.0 (0.5) 0.0464 0.0531 -1%
Placebo 2.9 (1.9) 3.3 (2.1) 0.4 (1.2) 15%